New treatments in myositis on the horizon.

Authors

Ingrid E Lundberg

Published in

EULAR rheumatology open. Volume 2. Issue 3. Pages 100233. Epub Sep 05, 2026.

Abstract

The idiopathic inflammatory myopathies (IIM), or briefly myositis, are a heterogeneous group of rare autoimmune diseases with high morbidity and mortality. Current treatment is based on high doses of glucocorticoids over long periods of time in combination with immunosuppressive drugs, with varying and often disappointing results. Therefore, there is a high unmet need for new therapies. Subgrouping patients with IIM based on clinical, histopathological and autoantibody profiles has facilitated identification of predominant molecular pathways, and this knowledge has been applied in recent successful clinical trials, and more trials are in the pipeline. This is exciting and promising news indicating possibilities to improve health and life for patients with IIM.

PMID:
42740902
Bibliographic data and abstract were imported from PubMed on 15 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.